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(aGVHD) prophylaxis in allogeneic hematopoietic cell transplantation (allo-HCT) recipients has been associated with toxicities. Toxicities may be managed by converting
CNI to sirolimus as often done in solid organ transplantation. This study aimed to
characterize allo-HCT patients who completely transitioned from tacrolimus to sirolimus and evaluate the incidence of aGVHD within 100 days post-transition, overall
survival (OS), and incidence of relapse.
Methods: Safety and efficacy data were collected at baseline and at day 30 and 90
post-transition from tacrolimus to sirolimus and at one-year post-HCT.
Results: Most patients who transitioned had acute leukemia, received a matched unrelated donor allo-HCT, and transitioned due to nephrotoxicity or neurotoxicity. The
resolution rate was 83% and 48% in the nephrotoxicity group, 78% and 61% in the
neurotoxicity group, 33% and 33% in the group that developed both nephrotoxicity
and transplant-associated thrombotic microangiopathy at 30 and 90 days of assessments, respectively. Patients who transitioned before day 55 post-allo-HCT were
more likely to develop new or worsening aGVHD. The one-year OS and relapse rates
were 37% and 20%, respectively.
Conclusions: The conversion from tacrolimus to sirolimus demonstrates promising
resolution of acute toxicities; however, overall mortality remains high.
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1 | I NTRO D U C TI O N

histocompatibility antigen disparity between the hematopoietic cell
donor and recipient, source of allogeneic hematopoietic cells, and

Acute graft-
versus-
host disease (aGVHD) is the second leading

intensity of conditioning regimen.4

cause of death in patients receiving allogeneic hematopoietic stem

Calcineurin inhibitors (CNIs), such as tacrolimus and cyclosporine,

cell transplant (allo-HCT).1 It often occurs after allo-
HCT within

have long been the standard of care for organ rejection prophylaxis

the first 100 days and is a reaction of donor immune cells against

in solid organ transplantation and GVHD prophylaxis in allo-HCT.1,5

host tissues that include the skin, liver, and gastrointestinal tract

However, CNIs are not devoid of risks. Long-term toxicities, such

(GI).

2,3

Numerous risk factors have been recognized to be associ-

as nephrotoxicity, neurotoxicity, and transplant-associated throm-

ated with increased incidence or severity of aGVHD, such as age,

botic microangiopathy (TA-TMA), can limit the use of tacrolimus.5,6

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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One strategy to manage these side effects is to convert the CNIs to

post-transition from tacrolimus to sirolimus, and at one-year post-

sirolimus.

HCT. The resolution of nephrotoxicity assessment was based on

Development of the mammalian target of rapamycin inhibi-

previous solid organ transplant trials which defined resolution of ne-

tors, such as sirolimus, could offer an alternative to CNIs to reduce

phrotoxicity as glomerular filtration rate improvement of 5 ml/min or

or eliminate CNI toxicities. The mammalian target of rapamycin

greater at time of assessment. Cockcroft gault calculation was used

inhibitors exert their immunosuppressive effect through a sep-

to estimate glomerular filtration rate.12,13 TA-TMA diagnosis and res-

arate mechanism and exhibit a different adverse effect profile

olution was determined by the Overall Thrombotic Microangiopathy

than CNIs.7,8 They inhibit the activation and proliferation of T-

Grouping which assessed the presence of normal coagulation assay,

lymphocytes which blocks growth factor-
induced transduction

presence of schistocytes, increase in lactate dehydrogenase, throm-

8

bocytopenia, decreased hemoglobin, decreased haptoglobin, and

Sirolimus has been used in the prevention and treatment of GVHD

negative Coombs’ test.6 Neurotoxicity was diagnosed and assessed

signals that mediate cellular division in response to alloantigens.
9

Its safety and efficacy have been compared

by the provider based on physical and neurologic examination and

in several trials to tacrolimus and were found to provide similar

after allo-H CT.

ruling out other causes of neurotoxicity, such as infection, preex-

10,11

GVHD-f ree survival.

Multiple randomized trials showed improved renal function with
the conversion from tacrolimus to sirolimus in solid organ transplant

isting conditions, medications. Neurotoxicity resolution was determined based on clinical assessment and documentation in the
medical records.

recipients.12,13 Significant improvement in neurotoxicity, secondary
to CNI use, was witnessed in liver transplant patients after the conversion from tacrolimus to sirolimus.8,14 There have not been any

2.3 | Statistical analysis

studies evaluating the safety and efficacy of this transition strategy
in allo-HCT patients.

Patient demographics, disease characteristics, toxicities, and allo-

The primary objective of this study was to characterize the allo-

HCT outcomes were summarized for all patients by aGVHD group (ie,

HCT population who transitioned from tacrolimus to sirolimus due

those with incidence of new or worsening aGVHD within 100 days

to toxicity or treatment failure. The secondary objectives of the

vs. those without). Categorical measures were summarized by fre-

study were to evaluate the incidence of new or worsening aGVHD

quencies and percentages and evaluated by Fisher's exact test or its

within 100 days post-transition from tacrolimus to sirolimus and to

generalization. Continuous measures were summarized by medians

evaluate overall survival (OS) and cumulative incidence of relapse at

and ranges (minimum and maximum) and assessed by Wilcoxon rank-

one-year post-HCT.

sum test. Associations between incidence of aGVHD and measures
of interest (eg, days post-allo-HCT and tacrolimus level) were deter-

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Study design and patients

mined using logistic regression models. OS was computed two ways:
(i) from allo-HCT date to date of last known vital sign and (ii) from
90 days after the start of sirolimus treatment (landmark). Patients
alive at their last follow-up date were administratively censored. OS
was estimated using the Kaplan-Meier method. One-year OS rates

This non-interventional retrospective cohort study was conducted

(landmark) were compared by aGVHD group using the log-rank test.

at The University of Texas MD Anderson Cancer Center. It included

To determine the association between OS (allo-HCT) and incidence

all patients aged 18 years or older who received an allo-HCT and

of developing aGVHD, aGVHD was included in a Cox proportional

were completely transitioned from tacrolimus to sirolimus from

hazards regression model as a time-dependent covariate. Cumulative

January 1, 2014, to December 31, 2018. Patients were excluded if

incidence of relapse was computed from allo-HCT date to date of re-

they were previously on aGVHD prophylaxis not containing tacroli-

lapse and determined using the competing risks method, where the

mus or if they developed refractory aGVHD that was treated with

competing risk included was death and patients who did not relapse

concomitant tacrolimus and sirolimus. This retrospective chart re-

and were still alive at their last follow-up date were censored.

view was approved by the Institutional Review Board.

2.2 | Data collection and assessment

3 | R E S U LT S
3.1 | Patient demographics

Patient demographics, pertinent medical history, disease characteristics, donor and stem cell source, conditioning regimen, im-

A total of 56 consecutive patients (median age 57.5 years; range 23-

munosuppressive therapy, laboratory values, GVHD, and adverse

72) met the inclusion criteria. The patients’ baseline characteristics,

effects were collected using the electronic medical record utilized

transplant data, and initial GVHD prophylaxis regimens are summa-

at the institution. Data were collected at baseline to characterize

rized in table 1. Most patients who transitioned had acute leukemia

allo-HCT patients who fit the inclusion criteria, at day 30 and 90

and received an allo-HCT from a matched unrelated donor (52%),

|
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TA B L E 1

Baseline characteristics of all patients

Characteristics

3

sirolimus while still receiving tacrolimus; the median time of overlap
Total
(N = 56)

Age
Median (range), years

57.5 (23-72)

<65 y (%)

46 (82)

≥65 y (%)

10 (18)

Sex
Male (%)

29 (52)

Female (%)

27 (48)

was 6.5 days (range 1-90).
Out of the 18 patients who received mycophenolate mofetil
(MMF) as part of the aGVHD prophylaxis regimen, 14 of 18 (77.8%)
patients were still on MMF at the time of conversion from tacrolimus
to sirolimus, while 4 of 18 (22.2%) patients were off MMF at time of
conversion. A total of 30 (53.6%) patients were bridged with corticosteroids during transition, defined as receiving corticosteroids for at
least 1 day; seven patients were in the aGVHD group and 23 were in
the non-aGVHD group. The median time of corticosteroid bridging
was 4 days (range 1-78).

HCT-Comorbidity Index
<3 (%)

26 (46)

≥3 (%)

30 (54)

3.3 | Complications leading to transition

Acute myeloid leukemia/Myelodysplastic
syndrome (%)

29 (52)

The reasons for transition from tacrolimus to sirolimus-based regi-

Acute lymphocytic leukemia (%)

8 (14)

are summarized in table 2. The most common reason for transition

Myeloproliferative disease (%)

8 (14)

was nephrotoxicity. There were 23 (41%) patients that transitioned

Lymphoma (%)

5 (9)

Chronic myeloid leukemia (%)

3 (5)

Multiple myeloma (%)

2 (4)

Chronic lymphocytic leukemia (%)

1 (2)

Disease State

Type of Transplant
Matched unrelated donor (%)

29 (52)

Haploidentical donor (%)

16 (29)

Matched related donor (%)

11 (20)

Conditioning Regimen

men were mainly nephrotoxicity, neurotoxicity, or TA-
TMA and

from tacrolimus to sirolimus due to nephrotoxicity alone, 18 (32%)
patients were transitioned secondary to neurotoxicity, and three
(5%) patients developed TA-TMA. There were three (5%) patients
who transitioned due to developing both nephrotoxicity and neurotoxicity and 3 (5%) transitioned due to concomitant nephrotoxicity and TA-TMA while on tacrolimus. Lastly, 6 (11%) patients were
transitioned from tacrolimus to sirolimus due to therapeutic failure
of tacrolimus, such as persistent subtherapeutic levels despite dose
increases and aGVHD development while on tacrolimus.
Sirolimus is often adjusted to maintain a serum trough concen-

Busulfan based (%)

36 (64)

tration of 3-12 ng/mL. At our institution, the target trough of siro-

Melphalan based (%)

16 (29)

limus is 5-10 ng/mL. The median time for sirolimus levels to reach

Other (%)

4 (7)

GVHD Prophylaxis Regimen
Tacrolimus/Methotrexate (%)

24 (43)

Tacrolimus/cyclophosphamide/mycophenolate
mofetil (%)

17 (30)

Tacrolimus/cyclophosphamide (%)

14 (25)

Tacrolimus/mycophenolate mofetil (%)

1 (2)

Day post-HCT of transition
Median (range), days

therapeutic level ≥5 ng/mL after transition was 7 days (range 0-41).
The median tacrolimus level prior to transitioning to sirolimus was

50.5 (6-98)

5.6 ng/mL (range 2.3-16.4) in all 56 patients. The group which did not
develop aGVHD had a median tacrolimus level of 6.1 ng/mL prior to
transitioning to sirolimus which was higher than the median level of
4.7 ng/mL in the group of patients that developed aGVHD.

3.4 | Resolutions of complications after transition
Resolutions of complications after transition are summarized in
table 2 for the 50 patients who transitioned due to toxicities. In

a busulfan-based conditioning regimen (64%), and a post-transplant

patients that transitioned from tacrolimus to sirolimus due to ne-

cyclophosphamide-based GVHD prophylaxis regimen (55%).

phrotoxicity alone, 19 out of 23 (83%) patients had resolution of
nephrotoxicity 30 days after transition. When nephrotoxicity was

3.2 | GVHD prophylaxis during transition

assessed 90 days after transition, resolution of nephrotoxicity was
sustained for 11 (48%) patients, while 4 (17%) had died and three
(13%) were lost to follow-up. Of the 18 patients who transitioned due

All patients received tacrolimus as part of their aGVHD prophylaxis

to neurotoxicity alone, 14 (78%) experienced resolution at 30 days

regimen. In 11 patients, tacrolimus was stopped the same day siroli-

after transition, two (11%) died before the assessment, and one (6%)

mus was started. In 21 patients, tacrolimus was stopped at least

was lost to follow-up. At the 90-day assessment, 11 of 18 patients

1 day before starting sirolimus. The remaining 24 patients started

(61%) had sustained resolution of neurotoxicity and seven (39%) died

4

|

TA B L E 2
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Resolution of complications
Day 30 assessment

Day 90 assessment

Complication

Total (N = 50)

Resolution

Death

No resolution

LFU

Resolution

Death

No resolution

LFU

Nephro

23

19

0

4

0

11

4

5

3

Neuro

18

14

1

2

1

11

7

0

0

TA-TMA

3

2

0

1

0

2

0

1

0

Nephro and neuro

3

2†

1

0

0

1

2

0

0

Nephro and TA-TMA

3

0

0

3

0

1‡

2

0

0

Abbreviations: LFU, lost to follow-up; Nephro, nephrotoxicity; Neuro, neurotoxicity; TA-TMA, transplant-associated thrombotic microangiopathy.
†

1 patient had resolution of nephrotoxicity only.

‡

Resolution of nephrotoxicity only.

TA B L E 3 Incidence of new or worsening aGVHD within
100 days post-transition

common primary cause of death was GVHD (acute and chronic;
15/39 [38%] patients), followed by recurrent or persistent disease
(13/39 [33%] patients) and viral or bacterial infection (6/39 [15%]

aGVHD

Total
(N = 14)

Organs affected

Grade I-II (%)

10 (71)

Lower GI, Upper GI, Skin, and Liver

Grade III-IV
(%)

4 (29)

Skin and Lower GI

patients). Five (13%) patients died from other known or unknown
causes. OS rates at one year and final assessment were 37% and
15%, respectively (Figure 1). Patients who developed aGVHD
post-transition experienced similar risk of death compared with
those who did not develop aGVHD. Figure 2 presents landmark
OS by aGVHD group. The one-year OS rates for the aGVHD pa-

before the assessment. From the three patients that developed TA-

tients was 29% compared with 67% for the non-a GVHD patients

TMA alone, resolution occurred in two (67%) patients at both day

(P = .051).

30 and day 90 assessments. Three patients were transitioned to

Fifteen of the 56 (27%) patients relapsed during the study, 14%

sirolimus due to developing both nephrotoxicity and neurotoxicity.

in the aGVHD group and 31% in the non-aGVHD group. The cumula-

Of those, one (33%) patient had resolution of both complications at

tive incidence of relapse at one year was 20% and at final assessment

day 30 and 90 assessments and one (33%) had only nephrotoxicity

was 30% for all patients.

resolution at 30 and died prior to the day 90 assessment.

3.5 | Incidence of aGVHD within 100 days post-
transition

4 | D I S CU S S I O N
While there has been literature evaluating the transition from tacrolimus to sirolimus in solid organ transplant, this is the first known

Fourteen (25%) patients developed new or worsening aGVHD within

study evaluating the efficacy and safety of the transition in allo-HCT

100 days post-transition (table 3). Five of the 14 patients had GVHD

patients.

at the time of transition. The majority of the aGVHD incidences were
grades I-II in the lower and upper GI, liver, and skin. Grade III-IV aGVHD
affecting the lower GI and skin occurred in four patients. Patients who

4.1 | Resolution

transitioned before day 55 post-allo-HCT were more likely to develop
new or worsening aGVHD (odds ratio [95% CI]: 6.00 [1.19, 30.15];

The 50 patients who transitioned from tacrolimus to sirolimus due

P = .030). We performed a subgroup analysis described in Table 4 that

to nephrotoxicity, neurotoxicity, and TA-TMA were included in the

compares the baseline characteristics between the patients that did

resolution assessment. Most patients were transitioned after devel-

not develop aGVHD and the patients that developed new or worsen-

oping nephrotoxicity, which was resolved in 83% (19/23) of patients

ing aGVHD within 100 days post-transition. The analysis was aimed to

by 30 days after transition. Eleven of the 19 patients sustained reso-

identify risk factors for developing aGVHD post-transition.

lution of nephrotoxicity at the 90-day assessment. When compared
to an open-label trial evaluating the conversion in renal allograft re-

3.6 | Survival and relapse

cipients, resolution in the intention to treat group was 38.2% and
33.6% at 12 months and 24 months, respectively.13 Thirty-and 90-
day assessments were not reported.

Thirty-nine of the 56 (70%) patients died during the study; 71% in

The second most common reason for transition was neurotoxic-

the aGVHD group and 69% in the non-a GVHD group. The most

ity. Seventy-eight percent of these patients experienced resolution

|
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TA B L E 4

5

Baseline characteristics by incidence of aGVHD post-transition

Characteristics

Non-aGVHD N = 42

aGVHD N = 14

P-value

Median (range), years

57.5 (25-72)

57.5 (23-6 4)

.92

<65 y (%)

32 (76)

14 (100)

.052

≥65 y (%)

10 (24)

0

<3 (%)

22 (52)

4 (29)

≥3 (%)

20 (48)

10 (71)

Acute myeloid leukemia/myelodysplastic syndrome (%)

24 (57)

5 (36)

Acute lymphocytic leukemia (%)

6 (14)

2 (14)

Myeloproliferative disease (%)

5 (12)

3 (21)

Lymphoma (%)

3 (7)

2 (14)

Chronic myeloid leukemia (%)

3 (7)

0

Multiple myeloma (%)

0

2 (14)

Chronic lymphocytic leukemia (%)

1 (2)

0

Matched unrelated donor (%)

24 (57)

5 (36)

Haploidentical donor (%)

13 (31)

3 (21)

Matched related donor (%)

5 (12)

6 (43)

Busulfan based (%)

28 (67)

8 (57)

Melphalan based (%)

10 (24)

6 (43)

Other (%)

4 (10)

0

Tacrolimus/methotrexate (%)

19 (45)

5 (36)

Tacrolimus/cyclophosphamide/mycophenolate mofetil (%)

14 (33)

3 (21)

Tacrolimus/cyclophosphamide (%)

8 (19)

6 (43)

Tacrolimus/mycophenolate mofetil (%)

1 (2)

0

55.0 (13-98)

36.0 (6-79)

.033

Median (range), ng/ml

6.1 (2.3-16.4)

4.7 (2.4-11.0)

.17

aGVHD vs. non-aGVHD Odds Ratio (95% CI)

0.84 (0.67, 1.04)

Age

HCT-Comorbidity Index
.22

Disease State
.16

Type of Transplant
.053

Conditioning Regimen
.28

GVHD Prophylaxis Regimen
.39

Day Post-HCT of Transition
Median (range), days
Tacrolimus Level Prior to Transition

at the 30 day assessment. Thirty-nine percent of patients with neu-

.11

4.2 | GVHD rate

rotoxicity died prior to day 90 assessment. Overall, the conversion
from tacrolimus to sirolimus demonstrated promising resolution of

In our study, 25% (14/56) of patients developed new or worsening

nephrotoxicity and neurotoxicity at the 30 and 90 days of follow-up.

aGVHD post-transition, thus this transition may be a reasonable op-

Only three patients transitioned from tacrolimus to sirolimus due

tion for patients that develop complications from CNIs. The rate of

to TA-TMA alone. All three patients received treatment with eculi-

aGVHD post-transition from tacrolimus to sirolimus has not been

zumab, a humanized monoclonal antibody, which has demonstrated

well reported in previous studies. Therefore, a direct comparison of

clinical efficacy for TA-TMA.15 Two patients had resolution at 30-

these rates cannot be made. Currently in the literature, the reported

and 90-
day assessment. With this small subset, it is difficult to

cumulative incidence of Grade II-IV aGVHD is 26%-56%, and the

evaluate the efficacy of transition from tacrolimus to sirolimus for

reported cumulative incidence of Grade III-IV aGVHD is 7%-21%.16

TA-TMA resolution; however, we have reported our experience with

Out of 14 patients that developed new or worsening aGVHD post-

TA-TMA previously.15

transition, three (21%) developed aGVHD at time of transition. Some

6
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ratio [95% CI]: 6.00 [1.19, 30.15]; P = .030). Therefore, it may be
reasonable to delay transition after day 55 post-allo-H CT if the
risk of transition delay does not outweigh the benefit of an earlier
transition. The level of tacrolimus prior to transition was not statistically different between groups. Additionally, the median time
needed for sirolimus to reach therapeutic level of ≥5 ng/mL was
7 days in both the non-a GVHD and aGVHD groups. Therefore, it
is unlikely the level of sirolimus affected the rate of aGVHD in our
patient population.

4.4 | Survival and relapse
The one-year OS rate was 37% for all patients in our study, lower
than what was documented in the literature. Most patients,
whose primary cause of death was aGVHD, experienced aGVHD
FIGURE 1

Kaplan-Meier estimates of overall survival

prior to transition. Studies have shown that developing aGVHD
decreases OS.16 This could be considered an additional risk factor that increases the mortality rate and decreases OS in patients
that have transitioned from tacrolimus to sirolimus. The literature
noted the in-h ospital mortality rate during the transplant admission was increased in patients developing nephrotoxicity, 37% in
non-dialysis-requiring renal failure and 84% in patients requiring
dialysis.18-20 Another trial evaluated the long-term outcomes from
CNI-induced neurotoxicity in allo-H CT patients, and the mortality
rate was as high as 80% at a median of 33 days (2-594) after neurotoxicity development.
Our results demonstrate worse survival outcomes compared to
the one-year survival rate of 78% reported in the general population of
matched related and matched unrelated allo-HCT.21 Since our patients
developed serious complications during HCT that led to a change in
immunosuppression, one could assume that these comorbidities negatively impacted overall survival. A literature review reported the estimated survival rate after developing grade three and four aGVHD
was 0%-43%.22 Therefore, our reported survival rate in patients that

F I G U R E 2 Kaplan-Meier estimates of overall survival by
aGVHD group (landmark)

developed new or worsening aGVHD, 29%, fits within the range of
what is documented in the literature. When patients who developed
aGVHD post-transition were compared to patients who did not, our

studies have indicated that the incidence of early-onset Grade III-IV

study showed a trend toward survival benefit in the landmark analysis.

aGVHD was associated with a higher risk of developing late aGVHD.

Although the conversion from tacrolimus to sirolimus demonstrated

This may have explained the persistent aGVHD witnessed in these

promising resolution of acute CNI-induced toxicities, the overall mor-

17

three patients.

tality rate still remains high. Caution should be considered when transitioning patients who have experienced aGVHD prior to transition or

4.3 | Risk factors

when transitioning patients before day 55 after allo-HCT.
The cumulative incidence of relapse for all patients in our study
was 30%, which is consistent with what has been reported in the

Patients in this study who transitioned earlier from tacrolimus to

literature, 20%-60% of patients. 23 Sirolimus inhibits tumor growth

sirolimus were significantly more likely to develop new or worsen-

by halting tumor cell proliferation, inducing tumor cell apoptosis,

ing aGVHD. It is important to note that a safe date of transition

and suppressing tumor angiogenesis and through the same mecha-

is indeterminant. Patients in both the aGVHD and non-a GVHD

nism can also block cancer cell proliferation. 24 Some studies demon-

groups were transitioned during a wide range of days after re-

strated that the use of sirolimus for GVHD prophylaxis in patients

ceiving allo-H CT. Patients who transitioned before day 55 post-

with lymphoma may lead to decreased incidence of disease progres-

allo-H CT experienced increased odds of developing aGVHD (odds

sion and improved survival after allo-HCT. 25

|
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4.5 | Limitations
There are several limitations to our study. This was a retrospective
study with inherent biases and no control arm. It is also possible
that eligible patients were missed due to the retrospective nature
of the study. Due to the infrequency of this transition, conducting a
prospective study would have been challenging. The rate of aGVHD
post-transition could have been affected by concomitant steroid use.
Corticosteroids were used intermittently as part of aGVHD treatment or to aid in aGVHD prophylaxis during transition from CNI to
sirolimus. Corticosteroids use during transition could have skewed
the efficacy of the transition, and therefore the rate of GVHD.
Other data on how aGVHD was treated and managed in the 14 patients who developed new or worsening GVHD were not collected.
Different GVHD treatment strategies could have been confounding
factors affecting the cumulative incidence of rate and OS among the
patients. Even though this is the only study to date evaluating the
safety and efficacy of this transition strategy in allo-HCT patients,
the sample size was not large enough to detect more risk factors
for developing aGVHD post-transition, besides time of transition.
Assessments for neurotoxicity were not objective and were based
on provider clinical assessment which could vary from provider to
provider. Some patients who transitioned due to nephrotoxicity
were receiving other nephrotoxic drugs. Nephrotoxicity resolution
could have been overestimated in patients receiving nephrotoxins
such as radiocontrast or antimicrobials and in patients infected with
BK virus.

5 | CO N C LU S I O N
Conversion from tacrolimus to sirolimus demonstrated promising
resolution of acute toxicities, such as nephrotoxicity and neurotoxicity. This approach seems to be feasible with a low risk of developing
aGVHD. However, providers need to be cautious with transitioning
patients’ earlier post-HCT since these patients may be at a higher risk
of developing new or worsening aGVHD with subsequent increased
risk of mortality. Caution should also be exercised in patients who
have an aGVHD diagnosis prior to the transition. Additional data
from larger studies and prospective data collection are needed to
confirm these results.
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